Embryo Transfer (CD19)
2026-12-08 (Tue)
CD19 · 2w5d
Day 5 Blastocyst
Flight to Taiwan
2027-07-10 (Sat)
33w – 34w
SFO → TPE (Direct)
Maternity Leave Start
2027-07-09 (Fri)
33w1d (Opt A)
Pre-flight Rest + CA SDI
Scheduled C-Section
2027-08-19 (Thu)
38w4d – 39w2d
Taipei Hospital (剖腹擇日)
Estimated Due Date
2027-08-26 (Thu)
40w0d (280d)
Clinical Baseline EDD
Clinical Background & Endometriosis Suppression Protocol
BCL6 = 1.8 · 8-Week Triple Oral Regimen Endometrial Biopsy ReceptivaDx Finding (2026-05)
The patient’s endometrial biopsy demonstrated a BCL6 H-score of 1.8 (clinical cutoff ≥ 1.4), establishing chronic endometriosis-mediated inflammation and progesterone receptor resistance. To restore endometrial receptivity before frozen embryo transfer (FET), she is undergoing 8 consecutive weeks (56 days) of triple oral therapy from Monday, 2026-09-21 to Sunday, 2026-11-15.
| Medication | Dosage & Route | Frequency | Mechanism & Target |
|---|---|---|---|
| Orilissa (elagolix) | 200 mg oral tablet | Twice Daily (BID) | Non-peptide GnRH antagonist; produces rapid, reversible pituitary LH/FSH and estradiol suppression without depot flare. |
| Letrozole (Femara) | 2.5 mg oral tablet | Once Daily (QD) | Type II aromatase inhibitor; blocks peripheral and ectopic lesion aromatase conversion of androgens to estrogens. |
| Juleber OCP | Desogestrel 0.15 mg / Ethinyl Estradiol 0.03 mg | Once Daily (QD) | Low-dose combined oral contraceptive; maintains ovarian quiescence, prevents escape follicular growth, and synchronizes cycle reset. |
Timeline Gantt Chart: Clinical Phases & Maternity Leave
2026-09 – 2027-12 (15 Months)Suppression
09/21 (Mon) – 11/15 (Sun)
CD19 Transfer
2026-12-08 (Tue)
6w Heartbeat
2027-01-04 (Mon)
20w Anatomy
2027-04-01 (Thu)
Fly to Taiwan
2027-07-10 (Sat)
C-Section Delivery
2027-08-16 – 08-18
Postpartum Center
08/24 – 09/23
Return SFO
Late Oct / Early Nov
Master Chronological Timeline & Protocols
26 Milestones| Date | Marker / GA | Location | Milestone Event | Key Action Items & Logistics |
|---|